Literature DB >> 15510325

Liver injury induced by the non-steroidal anti-inflammatory drug mefenamic acid.

N Somchit1, F Sanat, E H Gan, I A W Shahrin, A Zuraini.   

Abstract

INTRODUCTION: Non-steroidal anti-inflammatory drugs (NSAIDs) are used to treat musculoskeletal disorders, inflammation and to control pain. Virtually all NSAIDs are capable of producing liver injury ranging from mild reversible elevation of liver enzymes to severe hepatic necrosis.
METHODS: Mice were dosed intraperitoneally with mefenamic acid either one day at 100mg/kg and 200mg/kg, or 14 days dosing at 50mg/kg/day and 100mg/kg/day. Plasma was taken for alanine aminotransferase activity. Mice were sacrificed at the end of the study. Livers were removed and weighed. Liver samples were taken for histology. results: One-day doses of mefenamic acid revealed dose-dependent hepatocyte degeneration in the liver parenchyma. There were no significant changes in plasma alanine aminotransferase activity. Interestingly, 14-day daily doses induced hepatocellular necrosis, massive degeneration and inflammation. This was accompanied by a significant increase in plasma alanine aminotransferase activity and significant increase in the liver weight in the 100mg/kg/day mefenamic acid-dosed mice.
CONCLUSION: Results from this study suggest that mefenamic acid is capable of producing hepatotoxicity and care should be taken when prescribing or using this drug.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15510325

Source DB:  PubMed          Journal:  Singapore Med J        ISSN: 0037-5675            Impact factor:   1.858


  8 in total

1.  Mefenamic Acid induced nephrotoxicity: an animal model.

Authors:  Muhammad Nazrul Somchit; Faizah Sanat; Gan Eng Hui; Shahrin Iskandar Wahab; Zuraini Ahmad
Journal:  Adv Pharm Bull       Date:  2014-08-10

2.  TRPM3 and miR-204 establish a regulatory circuit that controls oncogenic autophagy in clear cell renal cell carcinoma.

Authors:  Daniel P Hall; Nicholas G Cost; Shailaja Hegde; Emily Kellner; Olga Mikhaylova; Yiwen Stratton; Birgit Ehmer; William A Abplanalp; Raghav Pandey; Jacek Biesiada; Christian Harteneck; David R Plas; Jarek Meller; Maria F Czyzyk-Krzeska
Journal:  Cancer Cell       Date:  2014-11-10       Impact factor: 31.743

3.  Characterization of the acyl-adenylate linked metabolite of mefenamic Acid.

Authors:  Howard Horng; Leslie Z Benet
Journal:  Chem Res Toxicol       Date:  2013-02-26       Impact factor: 3.739

4.  The nonenzymatic reactivity of the acyl-linked metabolites of mefenamic acid toward amino and thiol functional group bionucleophiles.

Authors:  Howard Horng; Leslie Z Benet
Journal:  Drug Metab Dispos       Date:  2013-08-23       Impact factor: 3.922

5.  FXR antagonism of NSAIDs contributes to drug-induced liver injury identified by systems pharmacology approach.

Authors:  Weiqiang Lu; Feixiong Cheng; Jing Jiang; Chen Zhang; Xiaokang Deng; Zhongyu Xu; Shien Zou; Xu Shen; Yun Tang; Jin Huang
Journal:  Sci Rep       Date:  2015-01-29       Impact factor: 4.379

6.  Significance of Multiple Bioactivation Pathways for Meclofenamate as Revealed through Modeling and Reaction Kinetics.

Authors:  Mary Alexandra Schleiff; Noah R Flynn; Sasin Payakachat; Benjamin Mark Schleiff; Anna O Pinson; Dennis W Province; S Joshua Swamidass; Gunnar Boysen; Grover P Miller
Journal:  Drug Metab Dispos       Date:  2020-11-25       Impact factor: 3.922

7.  Development of a convenient in vivo hepatotoxin assay using a transgenic zebrafish line with liver-specific DsRed expression.

Authors:  Xiaoyan Zhang; Caixia Li; Zhiyuan Gong
Journal:  PLoS One       Date:  2014-03-13       Impact factor: 3.240

8.  Immunomodulatory activity of mefenamic acid in mice models of cell-mediated and humoral immunity.

Authors:  Arham Shabbir; Hafiza Maida Arshad; Muhammad Shahzad; Sadia Shamsi; Muhammad Imran Ashraf
Journal:  Indian J Pharmacol       Date:  2016 Mar-Apr       Impact factor: 1.200

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.